Time trends and survival of marginal zone lymphoma over 25 years in Girona, Spain (1994–2018)
dc.contributor.author
dc.date.accessioned
2023-12-20T11:26:21Z
dc.date.available
2023-12-20T11:26:21Z
dc.date.issued
2023-06
dc.identifier.uri
dc.description.abstract
Objective
To analyze the incidence, incidence trends, and survival of marginal zone lymphomas (MZLs) in Girona and to describe these indicators based on the location in the case of extranodal MZLs.
Methods
Population-based study of MZL collected in the Girona Cancer Registry, 1994–2018. Sociodemographic data, tumor location, and stage were obtained from clinical records. Crude (CR) and age-adjusted (ASRE) incidence rates expressed per 100,000 person-years (p-y) were calculated. Joinpoint regression models were used for the trend analysis according to the MZL group. Five-year observed and net survival were analyzed.
Results
A total of 472 MZLs were included, 44 (9.3%) were nodal, 288 (61.0%) extranodal, 122 (25.9%) splenic, and the rest (n = 18) MZL, NOS. The CR for the MZL was 2.89 × 100,000 p-y (95% CI: 2.63–3.15), the ASRE was 3.26 × 100,000 p-y (95% CI: 2.97–3.57), and the annual percentage change (APC) was 1.6 (95% CI: 0.5–2.7). The ASRE for nodal MZL was 0.30 × 100,000 p-y (95% CI: 0.22–0.41) and showed an APC of 2.9% (95% CI: −16.4–26.6). For extranodal MZL, the ASRE was 1.98 × 100,000 p-y (95% CI: 1.76–2.23) and the APC was −0.4 (95% CI: −2.0–1.2). The most frequent locations of this type of MZL were the gastric (35.4%), skin (13.2%), and respiratory system (11.8%). The ASRE of the splenic MZL was 0.85 (95% CI: 0.71–1.02) with an APC of 12.8 (95% CI: 2.5–24.0). The 5-year net survival of MZL was 82.1% (95% CI: 76.3–86.5).
Conclusions
This study reveals differences in the incidence and trend of the incidence of MZL according to the subgroup, showing a significant increase in the overall MZL mainly due to splenic MZL type
dc.description.sponsorship
Agència de Gestió d'Ajuts Universitaris i de Recerca Grant Number: 2021 SGR 01511; Josep Carreras Leukaemia Research Institute Grant Number: FIJC1100
dc.format.mimetype
application/pdf
dc.language.iso
eng
dc.publisher
Wiley
dc.relation.isformatof
Reproducció digital del document publicat a: https://doi.org/10.1002/cam4.5935
dc.relation.ispartof
Cancer Medicine, 2023, vol. 12, núm. 11, p. 12343-12353
dc.relation.ispartofseries
Articles publicats (D-I)
dc.rights
Attribution 4.0 International
dc.rights.uri
dc.subject
dc.title
Time trends and survival of marginal zone lymphoma over 25 years in Girona, Spain (1994–2018)
dc.type
info:eu-repo/semantics/article
dc.rights.accessRights
info:eu-repo/semantics/openAccess
dc.type.version
info:eu-repo/semantics/publishedVersion
dc.identifier.doi
dc.identifier.idgrec
036815
dc.type.peerreviewed
peer-reviewed
dc.identifier.eissn
2045-7634